CA-SCIENTIST.COM
18.5.2020 08:57:09 CEST | Business Wire | Press release
Scientist.com, the pharma industry’s leading marketplace for outsourced research, announced today that it has joined with the UKCRC Tissue Directory and Coordination Centre (TDCC) to host a panel of experts to discuss current challenges in UK biobanking. The second webinar in the two-part series is scheduled for May 20, 2020, at 2:00 pm BST and will focus on how to enable biobanks to increase sample access in a transparent and compliant manner.
“We are excited to have assembled such distinguished panels on one of the most important topics within the UK biobanking community today—how biobanks can make their samples available to a wider audience for the use of drug discovery,” said Matt McLoughlin, VP of Compliance & Categories at Scientist.com. “It is critical that biobanks in the UK find simpler and more effective ways to connect with the research community to make human biospecimens available for pre-clinical and clinical research.”
The panel consist of experts in biobanking, including Phil Quinlan, PhD, Director at UKCRC TDCC; Alison Parry-Jones, PhD, Operations Director at Wales Cancer Bank; and Matt McLoughlin, VP of Compliance & Categories at Scientist.com.
Register for the free webinar, Overcoming Challenges in UK Biobanking, Part 2: Three Practical Approaches , scheduled for Wednesday May 20, 2020 at 2:00 pm BST.
The entire recording of Part 1: Maximizing the Use, Value and Impact of Human Samples , including highlights from the Q&A section, can be viewed on the UKCRC TDCC webinar debrief .
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saving time and money, reducing risk and providing access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, the Biotechnology Innovation Organization (BIO) and the US National Institutes of Health (NIH). Since its founding in 2007, Scientist.com has raised $39 million from 5AM Ventures, Leerink Transformation Partners and Heritage Provider Network among others.
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram .
About the UKCRC Tissue Directory and Coordination Centre
The mission of the UKCRC Tissue Directory and Coordination Centre (UKCRC TDCC) is to maximise the use, value and impact of the UK's human sample resources in the UK, and beyond. The UKCRC TDCC host a world-leading, research-enabling, and networked biobanking infrastructure to facilitate the discovery and use of the UK's human samples and data.
Run by a dedicated team across the University of Nottingham and University College London, the creation of the UKCRC TDCC was mandated by the UK Clinical Research Collaboration via their Vision for Human Tissue Resources. The UKCRC TDCC works to help researchers discover samples and data, help sample resources improve their data systems for sharing, and harmonise policy relating to the discovery and use of samples and data.
The work of the UKCRC TDCC is guided by the belief that the biomedical research ecosystem should be based on open standards, open-science, and pre-competitive collaboration.
The UKCRC TDCC also acts as the UK node for the European research infrastructure for biobanking, BBMRI-ERIC .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200517005040/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Jeito Capital Hits Record $1.2 Billion (€1 Billion)1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients8.4.2026 08:15:00 CEST | Press release
This record closing is the largest raise ever achieved by a fully independent European fund dedicated to Biopharma, validating Jeito’s patient-driven investment strategy, its multidisciplinary, collaborative expertise spanning from science to commercialization of medicines, and value creationIn five years, Jeito Capital has tripled its assets under management to €1.6 billion, firmly establishing itself among the top-tier global Biopharma investorsJeito II will build on Jeito I’s proven and differentiated strategy, investing in the most promising clinical Biopharma companies which address unmet patient needs and severe diseases, accelerate breakthrough therapeutic innovation, and deliver transformative benefits for patientsThis fundraise represents significant momentum for European Biopharma, strengthening its financial firepower and expertise to develop the next generation of global champions Jeito Capital (“Jeito”), a global independent private equity fund dedicated to Biopharma, toda
Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics8.4.2026 07:00:00 CEST | Press release
Hyaluronic acid product for knee osteoarthritis available in the EU and Switzerland from May 2026 Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis. A strategic return built on proven heritage With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of its offering. Synocrom™ is not a new name in the market. During the period in which Croma actively marketed the product, it became one of the leading hyaluronic acid brands in Europe and ranked among the top brands in its category. Its return therefore represents more than a portfolio expansion: it marks the continuation of a successful orthopaedic legacy and reconnects Croma with an important part of its history. The reintroduction of
Murata Begins Mass Production of Seven Automotive MLCCs with World-leading Capacitance for Their Rated Voltage and Size, Supporting Stable Operation of In-vehicle Systems and Greater Design Flexibility8.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has begun mass production of seven AEC-Q200-qualified multilayer ceramic capacitors (MLCCs) that achieve the world’s largest capacitance for a given rated voltage and size*, supporting stable operation of in-vehicle systems and greater design flexibility. Five parts in the GCM series are rated at 2.5-4 Vdc, targeting IC peripheral circuits in advanced driver assistance systems (ADAS) and autonomous driving (AD) applications. The remaining two MLCCs are rated at 25 Vdc for in-vehicle power line applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407486750/en/ [Murata Manufacturing Co., Ltd.] Seven automotive MLCCs In recent years, as ADAS and AD technologies advance, the number and performance level of systems installed in vehicles have continued to increase. As a result, demand for higher capacitance low-voltage MLCCs used around ICs has grown to e
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)7.4.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seven newly hired non-executive employees. The equity awards were granted on April 1, 2026 and consisted of options to purchase an aggregate of 117,445 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 55,875 shares. The options have an exercise price per share equal to $5.62, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted s
SLB OneSubsea and Subsea7 Sign Collaboration Agreement with PETRONAS Suriname7.4.2026 22:05:00 CEST | Press release
Partnership enables early engagement to co-develop cost-effective solutions and accelerate subsea development in Suriname Global energy technology company SLB (NYSE: SLB) today announced the signing of a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331210557/en/ SLB OneSubsea has signed a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea soluti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom